Results 141 to 150 of about 21,874 (160)

RON confers lapatinib resistance in HER2-positive breast cancer cells

Cancer Letters, 2013
Liguang Lou, Chengying Xie
exaly  

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

Cancer Letters, 2008
Yung-Jue Bang, , Seock-Ah Im
exaly  

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

Investigational New Drugs, 2013
Jan Schellens, Kevin Koch, Lot Devriese   +2 more
exaly  

Lapatinib-Associated Toxicity and Practical Management Recommendations

Oncologist, 2007
Beverly Moy, Moy Beverly
exaly  

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

Annals of Oncology, 2011
Antonello Vidiri, Stefania Gori, Giulio Metro   +2 more
exaly  

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

Pharmaceutical Research, 2011
Stephen Castellino, Patricia Steeg, Julie Lockman   +2 more
exaly  

Lapatinib for Advanced or Metastatic Breast Cancer

Oncologist, 2012
Jan Schellens, Jos Beijnen, Frans Opdam   +2 more
exaly  

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

Annals of Oncology, 2013
Yoshiya Horimoto, Raoul Charles Coombes, Jacqui Shaw   +2 more
exaly  

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

Annals of Oncology, 2010
Shin-Cheh Chen, Pierfranco Conte, Giuseppe Capri   +2 more
exaly  

The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis

European Journal of Cancer, 2017
Michele Ghidini, Veronica Lonati, Fausto Petrelli   +2 more
exaly